PGI15 COST PER REMISSION WITH VEDOLIZUMAB AND USTEKINUMAB FOR THE TREATMENT OF MODRATE TO SEVERELY ACTIVE CROHN'S DISEASE IN BRAZIL: PERSPECTIVE OF THE PRIVATE HEALTHCARE SYSTEM
May 1, 2020, 00:00
10.1016/j.jval.2020.04.372
https://www.valueinhealthjournal.com/article/S1098-3015(20)30560-X/fulltext
Title :
PGI15 COST PER REMISSION WITH VEDOLIZUMAB AND USTEKINUMAB FOR THE TREATMENT OF MODRATE TO SEVERELY ACTIVE CROHN'S DISEASE IN BRAZIL: PERSPECTIVE OF THE PRIVATE HEALTHCARE SYSTEM
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)30560-X&doi=10.1016/j.jval.2020.04.372
First page :
Section Title :
Open access? :
No
Section Order :
10238